Last reviewed · How we verify
NCT06205953: EUREKA
A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
trial in AL Amyloidosis in 400 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 January 2024 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 6 locations across Italy, Netherlands, Germany, Switzerland, Spain, Uruguay |
Conditions studied
- AL Amyloidosis — all drugs for AL Amyloidosis →
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Who can join
Adults 18 to 99, any sex, with AL Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Piecing together the intricate puzzle of organ recovery in AL amyloidosis.
Nuvolone M, Palladini G. · · 2024 · cited 2× · PMID 39359161 · DOI 10.1111/bjh.19810 -
Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.
Bellofiore C, Basset M, Nuvolone M, Nanci M, et al · · 2026 · PMID 41704548 · DOI 10.1002/hem3.70320
Verify or expand the search:
- PubMed search for NCT06205953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for AL Amyloidosis
Currently open trials in the same condition.
- NCT07448935 — One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS · recruiting
- NCT07448779 — Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment · recruiting
- NCT07079423 — Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis · Phase 2 · recruiting
- NCT06935162 — Teclistamab in Previously Treated AL Amyloidosis · Phase 2 · recruiting
- NCT06699394 — Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis · NA · recruiting
Other Fondazione IRCCS Policlinico San Matteo di Pavia trials
Trials by the same sponsor.
- NCT07534007 — Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zo · recruiting
- NCT07494344 — Italian Retrospective/Prospective Observational Study on Prosthetic Surgery in Patients With Congenital Coagulation Dise · recruiting
- NCT07356583 — Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights on · recruiting
- NCT07435207 — Thrombotic RIsk FActors in AL-goneurodystrophy · enrolling by invitation
- NCT07263802 — Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06205953 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Policlinico San Matteo di Pavia
- Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06205953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing